What is Kymera Therapeutics's PP&E (net)?

Kymera Therapeutics (KYMR) reported PP&E (net) of $41.62M in Q1 2026.

How has Kymera Therapeutics's PP&E (net) changed year-over-year?

Kymera Therapeutics's PP&E (net) decreased by 15.4% year-over-year, from $49.17M to $41.62M.

What is the long-term trend for Kymera Therapeutics's PP&E (net)?

Over 5 years (2020 to 2025), Kymera Therapeutics's PP&E (net) has grown at a 31.8% compound annual growth rate (CAGR), from $10.84M to $43.18M.

What does PP&E (net) mean?

Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Kymera Therapeutics KYMR PP&E (Net)

PP&E (Net) at other companies

PfizerPFE

$19.4B+5.8%

Johnson & JohnsonJNJ

$23.27B+11.5%

ImmunityBio, Inc.IBRX

$112.79M-16.6%

Krystal Biotech, Inc.KRYS

$153.58M+1.7%

Protagonist TherapeuticsPTGX

——

Immunovant, Inc.IMVT

——

Other financials

Income statement

See full

Revenue$34.4M+55.5%

Operating income-$84.2M-13.1%

Net income-$69.2M-5.6%

EPS (diluted)-$0.71+13.4%

Balance sheet

See full

Cash & equivalents$144.1M+60.2%

Total debt$82.2M-6.5%

Total equity$1.5B+95.8%

Total assets$1.7B+81.7%

Cash flow

See full

Operating cash flow-$88.8M-12.2%

CapEx$434.0K-7.1%

Free cash flow-$89.3M-12.1%

Valuation

See full

Market cap$7.44B+283%

Enterprise value$7.38B+280%

P/S144.5×+111×

Profitability

See full

Operating margin-697.7%+635pp

Net margin-612%+602pp

FCF margin-474%+92.4pp

Returns & leverage

See full

Return on equity-27.1%-3.7pp

Debt / equity0.1×-0.1×

Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kymera Therapeutics's PP&E (net)?: Kymera Therapeutics (KYMR) reported PP&E (net) of $41.62M in Q1 2026.
How has Kymera Therapeutics's PP&E (net) changed year-over-year?: Kymera Therapeutics's PP&E (net) decreased by 15.4% year-over-year, from $49.17M to $41.62M.
What is the long-term trend for Kymera Therapeutics's PP&E (net)?: Over 5 years (2020 to 2025), Kymera Therapeutics's PP&E (net) has grown at a 31.8% compound annual growth rate (CAGR), from $10.84M to $43.18M.
What does PP&E (net) mean?: Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.